Search

Displaying results 2011 - 2020 of 10000 in total
  1. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim

  2. Drug

    SU-11652

    go.drugbank.com/drugs/DB08009
    Experimental

    SU-11652 is a tyrosine kinase inhibitor.

  3. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly … least a partial response to prior first-line multiagent, multimodality therapy.

  4. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    Dimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

  5. Drug

    Tetracosactide

    go.drugbank.com/drugs/DB01284
    ApprovedInvestigational

    Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.

  6. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

  7. Drug

    Gadoversetamide

    go.drugbank.com/drugs/DB00538
    Approved

    Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases.

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  9. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol]. … [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

  10. Drug

    Anidulafungin

    go.drugbank.com/drugs/DB00362
    Approved

    Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. … There is preliminary evidence that it has a similar safety profile to caspofungin.

    Products: GIXOFU 100 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE